- Novavax Inc (NASDAQ:NVAX) has initiated the administration of the first booster doses of NVX-CoV2373 in the pediatric expansion of the PREVENT-19 pivotal Phase 3 trial.
- The study will evaluate the safety and immunogenicity of a third dose of NVX-CoV2373 among trial participants aged 12 through 17.
- All PREVENT-19 trial participants aged 12 through 17 are now eligible to receive a third booster dose of NVX-CoV2373.
- Related: Novavax's COVID-19/Influenza Combo Vaccine Shows Immunogenicity In Early-Study.
- The booster dose is identical to the active vaccine previously administered to the participants in a two-dose regimen (5 micrograms of recombinant spike protein plus 50 micrograms of Matrix-M adjuvant).
- It can be administered at least five months after receiving the active vaccine.
- Post-booster objectives include the assessment of the humoral immune response 28 days after the administration of the booster dose, as well as describing COVID-19 disease.
- Also See: Novavax's COVID-19 Vaccine Scores Green Light In India with First Approval For Adolescents
- Initial results are expected during 2H of 2022.
- Price Action: NVAX shares closed at $48.90 on Thursday.
